We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

78 hedge funds and large institutions have $445M invested in LENZ Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

36% more capital invested

Capital invested by funds: $327M → $445M (+$118M)

20% more funds holding

Funds holding: 65 → 78 (+13)

18% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

5.95% less ownership

Funds ownership: 74.08% → 68.13% (-6%)

Holders
78
Holders Change
+13
Holders Change %
+20%
% of All Funds
1.12%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
22
Increased
20
Reduced
17
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.61M
3
PHP
Parkman Healthcare Partners
Connecticut
+$3.09M
4
SSA
Schonfeld Strategic Advisors
New York
+$2.38M
5
Charles Schwab
Charles Schwab
California
+$1.82M

Top Sellers

1
EC
EcoR1 Capital
California
-$19.4M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.43M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$2.38M
4
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$1.74M
5
PM
Prosight Management
Texas
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$99.2M – – –
AWG
2
Alpha Wave Global
New York
$85.8M – – –
SB
3
Samsara BioCapital
California
$28.7M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$26.6M +$3.61M +162,510 +17%
7IH
5
72 Investment Holdings
Connecticut
$24.2M – – –
SAM
6
Sectoral Asset Management
Quebec, Canada
$23.2M -$2.38M -107,159 -10%
BlackRock
7
BlackRock
New York
$22.1M -$666K -30,023 -3%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$20.5M – – –
RI
9
RTW Investments
New York
$20.5M – – –
TCM
10
Tang Capital Management
California
$18.2M +$429K +19,324 +3%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$10.7M +$9.96M +448,631 New
EC
12
EcoR1 Capital
California
$8.23M -$19.4M -873,002 -72%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$8.03M -$490K -22,096 -6%
State Street
14
State Street
Massachusetts
$6.86M +$1.01M +45,600 +19%
IC
15
Ikarian Capital
Texas
$4.86M – – –
PHP
16
Parkman Healthcare Partners
Connecticut
$3.31M +$3.09M +139,357 New
Northern Trust
17
Northern Trust
Illinois
$3.08M +$1.07M +48,170 +59%
Charles Schwab
18
Charles Schwab
California
$2.93M +$1.82M +81,901 +197%
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$2.9M -$4.43M -199,602 -62%
SSA
20
Schonfeld Strategic Advisors
New York
$2.55M +$2.38M +107,300 New
Wealth Enhancement Advisory Services
21
Wealth Enhancement Advisory Services
Minnesota
$1.97M +$22 +1 +0%
Ameriprise
22
Ameriprise
Minnesota
$1.54M +$1.44M +64,941 New
BCM
23
BML Capital Management
Indiana
$1.42M -$86.9K -3,916 -6%
VCM
24
Vivaldi Capital Management
Illinois
$1.39M – – –
BFM
25
Boothbay Fund Management
New York
$1.29M – – –
1
2 3 4

LENZ Hedge Fund Activity: Q3 2024 in Review

78 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2024, worth a combined $445M — up 36% from $327M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new LENZ positions and 9 closed out — a net gain of 13 holders — while 20 added to existing stakes and 17 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $9.96M. The largest seller was EcoR1 Capital, cutting an estimated $19.4M.

  • 78 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2024, up from 65 in Q2 2024.
  • Funds reported $445M of LENZ Therapeutics stock for Q3 2024, up 36% quarter-over-quarter.
  • 22 funds opened new LENZ Therapeutics positions in Q3 2024 and 9 closed out, a net change of +13 holders.
  • The largest LENZ Therapeutics buyer in Q3 2024 was T. Rowe Price Associates, an estimated $9.96M added.
  • The largest LENZ Therapeutics seller in Q3 2024 was EcoR1 Capital, an estimated $19.4M sold.

Based on aggregated 13F filings for Q3 2024.